Table 1.
Indirect comparisons of outcomes among different treatments
| OS | |||||||||
| Donafenib | |||||||||
| 1.79 (0.64,5.21) | HAIC | ||||||||
| 1.4 (0.54,3.71) | 0.79 (0.38,1.62) | HAIC_Sorafenib | |||||||
| 0.84 (0.26,2.59) | 0.46 (0.18,1.15) | 0.59 (0.25,1.39) | Lenvatinib | ||||||
| 0.89 (0.33,2.53) | 0.5 (0.23,1.07) | 0.64 (0.32,1.28) | 1.07 (0.44,2.72) | SIRT | |||||
| 1.03 (0.28,4.06) | 0.58 (0.18,1.86) | 0.73 (0.24,2.27) | 1.25 (0.36,4.53) | 1.16 (0.48,2.8) | SIRT_Sorafenib | ||||
| 0.83 (0.35,1.95) | 0.46 (0.25,0.83) | 0.59 (0.38,0.9) | 0.99 (0.48,2.12) | 0.93 (0.53,1.57) | 0.8 (0.28,2.2) | Sorafenib | |||
| 0.77 (0.27,2.2) | 0.43 (0.22,0.82) | 0.55 (0.26,1.13) | 0.92 (0.38,2.23) | 0.86 (0.43,1.67) | 0.74 (0.24,2.2) | 0.93 (0.51,1.68) | TACE | ||
| 1.7 (0.5,5.75) | 0.95 (0.34,2.53) | 1.21 (0.44,3.19) | 2.05 (0.94,4.39) | 1.92 (0.68,5) | 1.65 (0.42,6.05) | 2.05 (0.84,4.9) | 2.2 (0.88,5.47) | TACE_Lenvatinib | |
| 0.88 (0.31,2.51) | 0.49 (0.24,0.99) | 0.63 (0.3,1.3) | 1.06 (0.45,2.51) | 0.99 (0.47,1.97) | 0.85 (0.27,2.59) | 1.06 (0.58,1.93) | 1.14 (0.74,1.79) | 0.52 (0.22,1.23) | TACE_Sorafenib |
| PFS | |||||||||
| TACE_Lenvatinib | |||||||||
| 0.79 (0.17, 3.94) | HAIC_Sorafenib | ||||||||
| 0.43 (0.15, 1.21) | 0.55 (0.16, 1.79) | Lenvatinib | |||||||
| 0.41 (0.08, 1.99) | 0.52 (0.22, 1.09) | 0.95 (0.26, 3.19) | HAIC | ||||||
| 0.38 (0.07, 1.93) | 0.48 (0.18, 1.22) | 0.88 (0.24, 3.16) | 0.91 (0.4, 2.27) | TACE_Sorafenib | |||||
| 0.32 (0.05, 1.84) | 0.4 (0.12, 1.3) | 0.73 (0.17, 3.06) | 0.76 (0.23, 2.77) | 0.84 (0.23, 3.03) | Donafenib | ||||
| 0.3 (0.06, 1.46) | 0.38 (0.15, 0.91) | 0.68 (0.2, 2.29) | 0.72 (0.3, 1.86) | 0.78 (0.31, 1.99) | 0.94 (0.28, 3.16) | SIRT | |||
| 0.29 (0.07, 1.23) | 0.36 (0.18, 0.68) | 0.66 (0.24, 1.82) | 0.7 (0.35, 1.46) | 0.76 (0.35, 1.67) | 0.9 (0.33, 2.51) | 0.96 (0.5, 1.9) | Sorafenib | ||
| 0.25 (0.05, 1.26) | 0.31 (0.12, 0.77) | 0.57 (0.15, 2.01) | 0.6 (0.27, 1.35) | 0.65 (0.36, 1.14) | 0.78 (0.21, 2.72) | 0.84 (0.33, 1.99) | 0.86 (0.39, 1.84) | TACE | |
| TTP | |||||||||
| HAIC | |||||||||
| 0.28 (0.06, 1.19) | HAIC_Sorafenib | ||||||||
| 0.33 (0.07, 1.52) | 1.15 (0.51, 3) | SIRT | |||||||
| 0.24 (0.06, 0.92) | 0.84 (0.51, 1.45) | 0.73 (0.34, 1.43) | Sorafenib | ||||||
| 0.19 (0.04, 0.84) | 0.68 (0.25, 1.6) | 0.58 (0.23, 1.16) | 0.8 (0.34, 1.58) | TACE | |||||
| 0.53 (0.09, 3.16) | 1.92 (0.51, 6.89) | 1.65 (0.44, 5.42) | 2.25 (0.66, 7.17) | 2.83 (1.03, 8.5) | TACE_Lenvatinb | ||||
| 0.29 (0.06, 1.31) | 1.04 (0.42, 2.48) | 0.9 (0.37, 1.88) | 1.23 (0.58, 2.44) | 1.54 (1.05, 2.51) | 0.55 (0.21, 1.43) | TACE_Sorafenib | |||
| AE | |||||||||
| SIRT | |||||||||
| 0.89 (0.12, 5.53) | HAIC | ||||||||
| 0.7 (0.05, 9.97) | 0.8 (0.06, 12.81) | Donafenib | |||||||
| 0.64 (0.11, 3.78) | 0.73 (0.14, 4.35) | 0.9 (0.06, 15.96) | TACE | ||||||
| 0.62 (0.06, 6.05) | 0.7 (0.04, 14.3) | 0.88 (0.03, 31.19) | 0.96 (0.05, 16.78) | SIRT_Sorafenib | |||||
| 0.43 (0.1, 1.79) | 0.49 (0.12, 2.2) | 0.61 (0.06, 5.99) | 0.67 (0.12, 3.42) | 0.7 (0.05, 10.07) | Sorafenib | ||||
| 0.31 (0.02, 4.48) | 0.36 (0.03, 5.42) | 0.44 (0.02, 10.59) | 0.49 (0.03, 7.61) | 0.51 (0.01, 16.78) | 0.73 (0.08, 6.89) | Lenvatinib | |||
| 0.17 (0.02, 1.49) | 0.2 (0.02, 1.84) | 0.25 (0.01, 3.86) | 0.27 (0.02, 2.61) | 0.28 (0.01, 6.3) | 0.4 (0.07, 2.08) | 0.55 (0.03, 8.58) | HAIC_Sorafenib | ||
| 0.15 (0.02, 0.9) | 0.16 (0.02, 1.07) | 0.21 (0.01, 3.13) | 0.23 (0.05, 0.76) | 0.23 (0.01, 4.18) | 0.34 (0.05, 1.68) | 0.46 (0.02, 6.89) | 0.84 (0.07, 8.67) | TACE_Sorafenib | |
| 0.08 (0, 1.57) | 0.09 (0, 1.88) | 0.11 (0, 4.18) | 0.12 (0.01, 1.72) | 0.12 (0, 5.16) | 0.17 (0.01, 3.19) | 0.24 (0.01, 9.21) | 0.43 (0.01, 12.81) | 0.52 (0.04, 6.05) | TACE_Lenvatinib |
| ORR mRECIST | |||||||||
| SIRT | |||||||||
| 0 (0, 0.85) | Sorafenib | ||||||||
| 0 (0, 0.25) | 0.28 (0.04, 1.86) | Lenvatinib | |||||||
| 0 (0, 0.17) | 0.23 (0.02, 2.14) | 0.81 (0.07, 9.39) | TACE | ||||||
| 0 (0, 0.15) | 0.2 (0.02, 2.12) | 0.7 (0.06, 8.17) | 0.87 (0.21, 3.71) | TACE_Sorafenib | |||||
| 0 (0, 0.14) | 0.15 (0.05, 0.45) | 0.55 (0.06, 5.16) | 0.68 (0.06, 8.94) | 0.78 (0.06, 11.47) | HAIC_Sorafenib | ||||
| 0 (0, 0.08) | 0.1 (0.02, 0.49) | 0.37 (0.04, 3.49) | 0.45 (0.07, 2.97) | 0.52 (0.05, 4.53) | 0.66 (0.08, 4.44) | HAIC | |||
| 0 (0, 0.06) | 0.07 (0.01, 0.7) | 0.24 (0.04, 1.67) | 0.3 (0.03, 2.92) | 0.35 (0.04, 2.69) | 0.44 (0.03, 5.75) | 0.67 (0.06, 8.25) | TACE_Lenvatinib | ||
| DCR mRECIST | |||||||||
| Sorafenib | |||||||||
| 0.61 (0.06,5.31) | TACE | ||||||||
| 0.57 (0.05,5.64) | 0.93 (0.23,3.82) | TACE_Sorafenib | |||||||
| 0.52 (0.08,3.25) | 0.84 (0.08,10.28) | 0.9 (0.08,10.91) | Lenvatinib | ||||||
| 0.53 (0.17,1.52) | 0.87 (0.08,10.18) | 0.92 (0.07,12.55) | 1.02 (0.12,8.58) | HAIC_Sorafenib | |||||
| 0.25 (0.05,1.02) | 0.41 (0.06,2.69) | 0.44 (0.05,3.86) | 0.49 (0.05,4.06) | 0.48 (0.07,2.86) | HAIC | ||||
| 0.09 (0.01,0.89) | 0.15 (0.01,1.52) | 0.16 (0.02,1.38) | 0.17 (0.02,1.17) | 0.17 (0.01,2.23) | 0.36 (0.03,4.14) | TACE_Lenvatinib | |||
| ORR RECIST | |||||||||
| Sorafenib | |||||||||
| 0.59 (0.03,10.8) | Lenvatinib | ||||||||
| 0.57 (0.02,15.33) | 0.97 (0.01,81.45) | Donafenib | |||||||
| 0.23 (0.02,2.2) | 0.39 (0.01,16.12) | 0.4 (0.01,21.12) | SIRT | ||||||
| 0.18 (0,14.3) | 0.3 (0.01,7.77) | 0.31 (0,72.24) | 0.79 (0.01,119.1) | TACE_Lenvatinib | |||||
| 0.1 (0.01,0.88) | 0.17 (0.01,3.39) | 0.18 (0,8.76) | 0.44 (0.02,11.25) | 0.56 (0.01,45.15) | TACE_Sorafenib | ||||
| 0.1 (0.01,0.98) | 0.17 (0.01,3.32) | 0.17 (0,9.3) | 0.43 (0.02,12.43) | 0.54 (0.01,42.95) | 0.96 (0.11,7.92) | TACE | |||
| 0.03 (0,0.39) | 0.05 (0,2.59) | 0.06 (0,3.56) | 0.14 (0,4.57) | 0.18 (0,27.94) | 0.32 (0.01,8) | 0.33 (0.01,9.78) | HAIC_Sorafenib | ||
| 0.03 (0,0.37) | 0.04 (0,1.67) | 0.05 (0,3.03) | 0.11 (0,4.14) | 0.14 (0,18.54) | 0.25 (0.01,4.81) | 0.26 (0.02,3.6) | 0.79 (0.02,35.16) | HAIC | |
| DCR RECIST | |||||||||
| SIRT | |||||||||
| 0.76 (0.29, 2.05) | Sorafenib | ||||||||
| 0.7 (0.13, 3.74) | 0.9 (0.23, 3.49) | Donafenib | |||||||
| 0.51 (0.12, 2.59) | 0.66 (0.21, 2.41) | 0.73 (0.13, 5.05) | Lenvatinib | ||||||
| 0.42 (0.11, 1.73) | 0.54 (0.2, 1.52) | 0.61 (0.12, 3.35) | 0.82 (0.22, 2.75) | TACE | |||||
| 0.38 (0.1, 1.39) | 0.49 (0.19, 1.2) | 0.54 (0.1, 2.75) | 0.73 (0.2, 2.32) | 0.9 (0.34, 2.23) | TACE_Sorafenib | ||||
| 0.2 (0.05, 0.9) | 0.26 (0.09, 0.83) | 0.29 (0.05, 1.73) | 0.4 (0.08, 1.72) | 0.49 (0.16, 1.49) | 0.54 (0.16, 2.03) | HAIC | |||
| 0.17 (0.04, 0.69) | 0.23 (0.07, 0.61) | 0.25 (0.04, 1.31) | 0.34 (0.06, 1.46) | 0.41 (0.08, 1.63) | 0.46 (0.1, 1.79) | 0.86 (0.16, 3.67) | HAIC_Sorafenib | ||
| 0.11 (0.01, 0.98) | 0.14 (0.02, 1.02) | 0.16 (0.02, 1.77) | 0.21 (0.05, 0.93) | 0.26 (0.04, 1.84) | 0.29 (0.05, 2.16) | 0.54 (0.07, 4.66) | 0.63 (0.08, 6.42) | TACE_Lenvatinib |
Comparisons should be read from left to right. HRs (95% CrIs) for comparisons are in the cells shared by the column-defining and row-defining interventions. Italicized cells are significant. For OS, PFS, and TTP, an HR < 1 favors the row-defining treatment. For AE, an OR < 1 favors the row-defining treatment. For ORR mRECIST, DCR mRECIST, ORR RECIST, and DCR RECIST, an OR < 1 favors the column-defining treatment
HAIC Hepatic arterial infusion chemotherapy, TACE Transarterial chemoembolization, SIRT Selective internal radiation therapy